

**Table 1** Neurological diseases modeled with iPSC cells

Disease	Gene	Cell type differentiated from iPSCs	Drug tests	References
Adrenoleukodystrophy	ABCD1	Oligodendrocytes and neurons	Lovastatin, 4-phenylbutyrate	(Jang <i>et al.</i> 2011)
Alzheimer's disease	PS1, PS2, APP, sporadic	Cortical neurons	$\gamma$ -, $\beta$ -secretase inhibitor, docosahexaenoic acid	(Yagi <i>et al.</i> 2011; Israel <i>et al.</i> 2012; Kondo <i>et al.</i> 2013)
Amyotrophic lateral sclerosis	SOD1, VAPB, TDP43	Motor neurons and glial cells	Anacardic acid, trichostatin A, spliceostatin A, garcinol	(Dimos <i>et al.</i> 2008; Mitne-Neto <i>et al.</i> 2011; Bilican <i>et al.</i> 2012; Egawa <i>et al.</i> 2012)
Cockayne's syndrome	ERCC6	iPSCs and neurons	N/A	(Andrade <i>et al.</i> 2012)
Down syndrome	Trisomy 21	Neurons and neural progenitors	N/A	(Park <i>et al.</i> 2008; Li <i>et al.</i> 2012; Weick <i>et al.</i> 2013)
Dravet syndrome	SCNA1A	GABAergic neurons	N/A	(Higurashi <i>et al.</i> 2013; Jiao <i>et al.</i> 2013; Liu <i>et al.</i> 2013b)
Familial dysautonomia	IKBKAP	Neural crest progenitor cells	Kinetin, SKF-86466	(Lee <i>et al.</i> 2009, 2012)
Fragile X-associated tremor/ataxia syndrome	FMR1	Neurons	N/A	(Urbach <i>et al.</i> 2010; Liu <i>et al.</i> 2012b)
Huntington's disease	HTT	Glutamatergic neurons and GABAergic neurons	N/A	(Park <i>et al.</i> 2008; Zhang <i>et al.</i> 2010; An <i>et al.</i> 2012; Camnasio <i>et al.</i> 2012; HD iPSC Consortium 2012; Jeon <i>et al.</i> 2012; Juopperi <i>et al.</i> 2012)
Machado-Joseph disease	ATXN3	Glutamatergic neurons	Calpain	(Koch <i>et al.</i> 2011)
Parkinson's disease	LRRK2, PINK1, SNCA, PARKIN, sporadic	Dopaminergic neurons	Coenzyme Q10, rapamycin, GW5074, LRRK2-IN1, PD0325901	(Devine <i>et al.</i> 2011; Nguyen <i>et al.</i> 2011; Seibler <i>et al.</i> 2011; Cooper <i>et al.</i> 2012; Imaizumi <i>et al.</i> 2012; Liu <i>et al.</i> 2012a; Rakovic <i>et al.</i> 2012; Sanchez-Danes <i>et al.</i> 2012; Reinhardt <i>et al.</i> 2013)
Rett's syndrome	MECP2, CDKL5	Neurons and neural progenitor cells	IGF1, gentamicin	(Marchetto <i>et al.</i> 2010; Muotri <i>et al.</i> 2010; Ananiev <i>et al.</i> 2011; Cheung <i>et al.</i> 2011; Ricciardi <i>et al.</i> 2012)
Schizophrenia	DISC1, sporadic	Neurons	Loxapine, valproic acid	(Brennand <i>et al.</i> 2011; Chiang <i>et al.</i> 2011; Pedrosa <i>et al.</i> 2011; Paulsen Bda <i>et al.</i> 2012)
Spinal muscular atrophy	SMN1	Motor neurons	Valproic acid, tobramycin	(Ebert <i>et al.</i> 2009; Chang <i>et al.</i> 2011)
Spinal and bulbar muscular atrophy	CAG repeat in the androgen receptor gene	Motor neurons	17-allylaminogeldanamycin	(Nihei <i>et al.</i> 2013)

level, defects develop in the circuits linking the cerebrum and the basal ganglia to which dopaminergic neurons project, and patients exhibit stereotypical motor symptoms, including bradykinesia, rigidity, tremors, and postural instability.

Previous research indicates that approximately 10% of PD patients have a form of disease that is caused by a mutation in a specific gene, and whose occurrence is termed 'familial'. For example, familial PD develops because of mutations in

the *LRRK2*, *PINK1*, *SNCA*, *PARKIN*, *DJ-1*, *ATPIA3*, *UCHL1*, and *GBA* genes. These genes are also thought to play an important role in the pathogenetic mechanism of sporadic Parkinson's disease. Because the motor symptoms do not develop until close to 70% of the dopaminergic neurons in the substantia nigra are lost, the molecular mechanism that predominates during the initial stage of PD remains unknown. However, iPS cells derived from PD patients can theoretically serve as a useful disease model by providing a tool to investigate the time course of changes from the onset of PD until the pathology has become apparent. Especially, the iPS-derived dopaminergic neuron is reasonable as PD patients have substantial loss of these neurons during the disease. We therefore focused our recent research efforts toward establishing iPS cells from early-onset familial PD (PARK2) patients with a mutation in the *PARKIN* gene to investigate the efficacy of disease-specific iPS cells for modeling purposes (Imaizumi *et al.* 2012).

We prepared PARK2 iPS cells by using recombinant retrovirus vectors to introduce the four aforementioned reprogramming genes, that is, *Oct4*, *Klf4*, *Sox2*, and *c-Myc*, into the skin cells of two PARK2 patients, patient PA and patient PB (Imaizumi *et al.* 2012). First, based on previous research on animal models of PD, we assumed that these patients would have higher levels of oxidative stress than normal individuals. Hence, we analyzed the amounts of reactive oxygen species (ROS) and reduced glutathione (GSH) in the neurons induced from PARK2 iPS cells. The results showed an inverse relationship between low GSH content and high ROS levels. We also observed activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway (Zhang *et al.* 2011), which serves as a defense mechanism against intensified oxidative stress. These observations are consistent with previous data showing a predominant decrease in GSH and a concomitant increase in Nrf2 signaling in the substantia nigra of the postmortem brains of PD patients (Venkateshappa *et al.* 2012; Bassik *et al.* 2013). Thus, oxidative stress is apparently already high in the brain before the onset of Parkinson's disease and during the initial stages after its onset.


In support of the above-described work, the dopamine D1/D2 receptor antagonist apomorphine (Jang *et al.* 2013), the selective monoamine oxidase B inhibitor deprenyl (Benraiss *et al.* 2013), and the dopamine D2 receptor antagonist bromocriptine (Merkle and Eggan 2013), all of which are used clinically as drugs for the treatment of PD, up-regulate the Nrf2 pathway together with their main pharmacological effects. Moreover, the anti-convulsant drug zonisamide has a protective effect on dopaminergic neurons that is mediated by its dopamine synthesis-stimulating and mild monoamine oxidase-inhibiting actions; however, the drug also activates the synthesis of GSH, which is governed by the Nrf2 pathway (Liu *et al.* 2012b). Therefore, the therapeutic indications for zonisamide have been expanded to include

its use as an anti-parkinsonian agent. Thus, if zonisamide can directly activate the central Nrf2 pathway in a more efficient manner, it is expected to find utility as a highly effective drug for the prevention of the onset and/or progression of PD.

Mitochondria are essential intracellular organelles that function in energy production. Mitochondria release significant amounts of ROS as byproducts of energy metabolism. For this reason, mitochondrial energy production is considered to be the main cause of oxidative stress. Up until now, it has been a technical challenge to make detailed structural observations of the mitochondria obtained from the post-mortem brain tissue of PD patients, because of the need to minimize chemical changes in the tissues caused by cell death. As an alternative approach, we conducted detailed electron microscopic observations of the mitochondria in neurons induced from the iPS cells of PARK2 patients. Interestingly, abnormal mitochondria were observed in the iPS-derived neurons originating from both of the PARK2 patients investigated in this study, patient PA and patient PB (Fig. 2). Because no abnormal mitochondria were observed in PARK2-derived fibroblasts or in the PARK 2 iPS cells themselves, these abnormal organelles would appear to be a neuron-specific phenomenon.


In addition, the PARKIN protein is reportedly involved in mitochondrial autophagy (mitophagy) (Narendra *et al.* 2008; Matsuda *et al.* 2010). Therefore, we employed the mitochondria uncoupler carbonyl cyanide *m*-chlorophenyl hydrazone to reduce mitochondrial membrane potential. carbonyl cyanide *m*-chlorophenyl hydrazone caused the inner membrane of the mitochondria of neurons derived from healthy subjects to disappear, whereas no disappearance of the inner membrane was observed in the neurons derived from the iPS cells of PARK2 patients. These findings suggest that abnormal mitochondria may have accumulated in the cells, because the mechanism that controls mitochondrial quality does not function properly in PARK2 iPS cell-derived neurons (Fig. 3).

Accumulation of  $\alpha$ -synuclein-rich Lewy bodies has been reported in the neurons of patients with sporadic Parkinson's disease, based on analyses of postmortem brain tissue (Shults 2006). However, it appears that Lewy bodies usually do not accumulate in the postmortem brain tissue of PARK2 patients (Farrer *et al.* 2001). We therefore analyzed the postmortem brain tissue of PARK2 patient PA. Surprisingly, we observed an abundance of  $\alpha$ -synuclein in the brain tissue of this patient. On the other hand, an analysis of the postmortem brain tissue of the father of patient PB, who had an identical *PARKIN* gene mutation and a similar genetic background as patient PB, revealed no  $\alpha$ -synuclein buildup. Next, we analyzed the expression of  $\alpha$ -synuclein in the iPS cell-induced neurons of patient PA and patient PB. A significant accumulation of  $\alpha$ -synuclein was found only in the iPS cell-induced neurons of patient PA, thus mimicking the situation in the patient's postmortem brain tissue. No such



**Fig. 2** Summary of the results of our study with PARK2 induced pluripotent stem (iPS) cell-derived neurons. An analysis of familial Parkinson's disease (PD) (PARK2) patient-derived iPS cells in which the *PARKIN* gene is defective revealed an increase in oxidative stress, abnormal mitochondrial morphology, and low mitochondrial quality. In addition,  $\alpha$ -synuclein accumulation was observed in the neurons originating from PARK2 patient (patient PA)-derived iPS cells.

The same patient showed Lewy body accumulation in the postmortem brain. Based on these results, further analyses using disease-specific human iPS cell-derived neurons should make it possible to reproduce the pathology and degree of disease progression in patients' brains, and to analyze pathological conditions that are close to those observed *in situ*.



**Fig. 3** Working model for familial Parkinson's disease (PD) risk factors: mediated mitochondrial quality control. Impaired mitochondria that have a low membrane potential develop as a result of increased oxidative stress and other factors. Mitochondrial quality is maintained by the familial PD factors PINK1 (PARK6) and PARKIN (PARK2). These factors pass into impaired mitochondria and guide the mitochondria toward degradation. DJ-1 (PARK7), another familial Parkinson's disease factor, is involved in a thioredoxin-mediated mechanism that protects mitochondria against oxidative stress, and a low mitochondrial membrane potential has been reported in LRRK2 mutants (PARK8). In addition, mutation of ATPase type 13A2

(ATP13A2, or PARK9), an  $H^+$ -ATPase involved in lysosomal acidification, causes abnormal lysosome function and abnormal protein degradation. On the other hand,  $\alpha$ -synuclein oligomers cause mitochondrial impairment in familial PD (PARK1, 4) and are associated with a missense abnormality of the gene (SNCA) that encodes  $\alpha$ -synuclein. In this case, a negative feedback loop is formed in which the mitochondrial impairment acts as a trigger for the formation of  $\alpha$ -synuclein oligomers. These results strongly suggest that a breakdown of quality control in the impaired mitochondria plays a critical role in the onset of PD.

accumulation was observed in the iPS cell-induced neurons of patient PB, which was consistent with the analysis of the patient's father's postmortem brain tissue.

This series of findings demonstrated that is possible to model many aspects of the cellular changes seem in patients. We still have a long way to go in modeling the

disease—especially the 3D organization and different cell types including glia, etc.

Many additional studies of iPS cells originating from familial PD patients (involving *LRRK2*, *PINK1*, *SNCA*, and *PARKIN* gene mutations) have been reported by other groups (see references in Table 2). Thus, by utilizing these disease-specific iPS cells, an investigator can actually reproduce the pathology of an individual patient's disease in a test tube. Furthermore, disease-specific iPS cells are proving extraordinarily useful in analyzing disease pathology in greater detail than that afforded by other methods (Table 2).

In addition, replication experiments with isogenic iPS cells, and rescue experiments via genetic repair, are likely to allow the precise analysis of pathogenetic mechanisms resulting from changes in single genes. A variety of innovations have made the performance of these experiments tenable, including the development of the helper-dependent adenoviral vector (Suzuki *et al.* 2008), zinc-finger nucleases (Zhou *et al.* 2009), transcription activator-like effector nucleases (TALENs) (Miller *et al.* 2011), and the CRISPR-Cas9 system (Cong *et al.* 2013; Mali *et al.* 2013) (Fig. 2). For example, Reinhardt *et al.* (2013) demonstrated neurite outgrowth abnormalities, induction of dopaminergic neuron death by the addition of 6-hydroxydopamine, tau and  $\alpha$ -synuclein deposition, and gene expression changes in dopaminergic neurons induced from iPS cells prepared from a patient with a *LRRK2* gene mutation (G2019S mutation). The investigators also established patient-specific iPS cells in which the G2019S mutation was repaired with zinc-finger nucleases, as well as isogenic leucine-rich repeat kinase 2 (*LRRK2*) iPS cells in which the G2019S mutation was introduced into normal cells. These iPS cells were used to show that the dopaminergic neuron abnormalities stemmed from a gain-of-toxic-function mutation of *LRRK2* and an enhanced extracellular signal-regulated kinase 1/2 phosphorylation. However, it is essential to conduct further isogenic control and rescue experiments to confirm the phenotype obtained using patient/disease-specific iPS cells for the analyses of disease-specific iPS cells derived from many monogenic mutation diseases, and not just PD.

### Challenges in modeling sporadic PD with patient-derived iPS cells

Unlike diseases caused by deletions or mutations within a specific gene (i.e., the familial Parkinsonism-related genes *LRRK2*, *PINK1*, *SNCA*, or *PARKIN*), it is not easy to construct human disease models for sporadic diseases in a test tube, even by using disease-specific iPS cells. The difficulty is because of the fact that these diseases are impacted by environmental as well as genetic factors. Nonetheless, a recent study successfully modeled certain aspects of the sporadic PD and *LRRK2* PD by using neurons derived from a variety of patient-specific iPS cells

(Sanchez-Danes *et al.* 2012). The results showed that either sporadic PD- or *LRRK2*-PD-iPS-derived dopaminergic neurons showed morphological alterations as well as alterations in autophagic clearance. This study demonstrates that phenotypes in neurons representing *LRRK2* mutation were also observed in those from sporadic PD patients. These phenotypes associated with sporadic and *LRRK2* PD might be helpful to understand pathogenesis of sporadic PD.

### iPS cells based human disease models for genetic and sporadic AD

Recent work using neurons derived from the iPS cells of sporadic AD patients revealed an accumulation of amyloid  $\beta$ , as was observed previously in neurons derived from the iPS cells of familial AD patients with mutations in *PRESENILIN1*, *PRESENILIN2*, or amyloid precursor protein (APP) (Yagi *et al.* 2011; Israel *et al.* 2012). Presenilin 1 and 2 function as components of the  $\gamma$ -secretase intra-membrane protease complex. Although a  $\gamma$ -secretase inhibitor effectively inhibited the amyloid  $\beta$  buildup in neurons derived from the iPS cells of familial AD patients with *PRESENILIN1* and *PRESENILIN2* mutations, a  $\beta$ -secretase inhibitor, but not a  $\gamma$ -secretase inhibitor, engendered the same effect in neurons derived from the iPS cells of sporadic AD patients and APP-mutant familial AD patients (Yagi *et al.* 2011; Israel *et al.* 2012). Moreover, neurons derived from the iPS cells of APP-mutant patients and one of two sporadic AD patients (patient 1) showed an accumulation of A $\beta$  oligomers, as well as increased endoplasmic reticulum and oxidative stress. Interestingly, docosahexaenoic acid treatment ameliorated the stress response in the sporadic AD iPS cell-derived neurons of patient 1, but had no effect on the iPS cell-derived neurons originating from the other sporadic AD patient (Kondo *et al.* 2013).

Thus, while there continues to be room for further experimentation, these observations reveal the impressive capacity of iPS cell research to elucidate pathological phenomena and to judge the clinical effectiveness of drugs in sporadic as well as genetic diseases. Furthermore, the likelihood that iPS cell technology will lead to the development of new strategies and methods of disease treatment seems high.

### Potential applications of disease-specific iPS cells for drug screening

In recent years, several analyses have utilized disease-specific iPS cells to explore the pathogenetic mechanisms of disease. In addition, a number of attempts to utilize these cells for drug screening have also been reported. For instance, Lee and colleagues established iPS cells from patients with FD, a disorder caused by a point mutation in

**Table 2** Familial PD modeled with iPSC cells

Gene	Mutations	iPSC-derived cells	Phenotype in human iPSC-derived cells	Use of isogenic & gene corrected iPSC	Drug testing	References
SNCA	Triplication of SNCA	Dopaminegic neurons	Double amount of alpha-synuclein protein	N/A	N/A	Devine <i>et al.</i> 2011
Parkin	Heterozygous deletions of exon 3 and exon 5/Homozygous deletion of exon 3	Dopaminegic neurons	Increased spontaneous dopamine release; Decreased dopamine uptake and dopamine transporter-binding sites; Elevated ROS by increasing MAO transcripts	Lentiviral expression of WT-parkin	N/A	Jiang <i>et al.</i> 2012
	Homozygous deletion of exon 2-4/Homozygous deletion of exon 6,7	Neural cells including dopaminergic neurons	Increased oxidative stress; Abnormal mitochondrial morphology and impaired mitochondrial homeostasis; Accumulation of alpha-synuclein protein	N/A	N/A	Imaizumi <i>et al.</i> 2012
PINK1	Q456X nonsense/V170G missense	Dopaminegic neurons	Impaired recruitment of PARKIN to mitochondria; Increased mitochondrial copy number; Up-regulation of PGC-1alpha	Lentiviral expression of wild-type PINK1	N/A	Seibler <i>et al.</i> 2011
PINK1/LRRK2	V170G missense	Dopaminegic neurons	Lack of Valinomycin-induced mitophagy	N/A	N/A	Rakovic <i>et al.</i> 2012
	Q456X nonsense (PINK1)/Heterozygous R1441C and homozygous G2019S mutation (LRRK2)	Neural cells including dopaminergic neurons	Production of reactive oxygen species (PINK1); Mitochondrial respiration (PINK1 and LRRK2); Proton leakage (PINK1); Intraneuronal movement of mitochondria (LRRK2)	N/A	Coenzyme Q10, rapamycin, or GW5074	Cooper <i>et al.</i> 2012
LRRK2	Homozygous G2019S mutation	Dopaminegic neurons	Increased expression of oxidative stress-response genes (HSPB1, NOX1, and MAOB) and alpha-synuclein protein; Sensitive to caspase-3 activation and cell death caused by hydrogen peroxide, MG-132, and 6-hydroxydopamine	N/A	N/A	Nguyen <i>et al.</i> 2011
	Homozygous G2019S mutation	Neural stem cells	Susceptibility to proteasomal stress; Passage-dependent deficiencies in nuclear-envelope organization; Clonal expansion and neuronal differentiation	Isogenic corrected LRRK2 iPSC/mtLRRK2 KI ESC	LRRK2-In-1	Liu <i>et al.</i> 2012a

Table 2 (continued)

Gene	Mutations	iPSC-derived cells	Phenotype in human iPSC-derived cells	Use of isogenic & gene corrected iPSC	Drug testing	References
LRRK2/sporadic	G2019S mutation/Sporadic mutation	Dopaminergic neurons	Dysregulation of CPNE8, MAP7, UHRF2, ANXA1, and CADPS2; Increased extracellular signal-regulated kinase 1/2 (ERK) phosphorylation; Increased expression of MAPT mRNA and TAU protein as well as increased alpha-synuclein protein; Neurite outgrowth phenotype; Increased sensitivity to 6-Hydroxydopamine, rotenone and oxidative stress	Isogenic corrected LRRK2 iPSC/mLRRK2 KI iPSCs	LRRK2-IN1, PD0325901	Reinhardt <i>et al.</i> 2013
LRRK2/sporadic	G2019S mutation/Sporadic	Dopaminergic neurons	Increased accumulation of alpha-synuclein; Fewer and shorter neurites; Increased apoptotic cells; Abnormal autophagic clearance	N/A	N/A	Sanchez-Danes <i>et al.</i> 2012

the *IKBKAP* (inhibitor of nuclear factor- $\kappa$ B kinase complex-associated protein) gene (Lee *et al.* 2009). Neural crest progenitor cells induced from the iPS cells of FD patients exhibited decreases in *IKBKAP* expression levels, reduced differentiation efficiency into neurons, and attenuated migratory ability (Lee *et al.* 2009). The same investigators also screened 6912 compounds in an effort to uncover drugs capable of increasing the expression of the *IKBKAP* gene in the induced FD patient-derived neural crest precursor cells. One of the hit drugs was termed 'SKF-86466', which has since been confirmed to augment the expression of nervous system marker genes in the induced neural crest precursor cells (Lee *et al.* 2012). These results indicate that large-scale screening of chemical libraries with patient-derived cells, an impossible goal in the past, is rapidly becoming a reality through the utilization of disease-specific iPS cells.

#### Future directions using disease-iPS cells

Recent advances in the iPS cell technology enable us to study not only monogenetic diseases but also sporadic disease. Furthermore, isogenic iPSC cell controlled with the same genetic background would be more adequate to analyze the subtle changes in disease models. However, there are still some limitations in iPS cell technology. For example, current iPSC cell-derived neurons showed poor maturational state. Patani *et al.*, showed that transcriptome profile of ES cell-derived neurons was more similar to fetal neurons rather than adult ones (Patani *et al.* 2012). Therefore, current iPSC cell-derived neurons were not fully suitable for late-onset neurological disease, such as AD and PD, and disorders of neuronal circuits, such as autism and epilepsy. Moreover, the iPSC cell-derived neurons following well-established neural differentiation protocols were still showed mixed population. For example, purity of ES cell-derived midbrain dopaminergic neurons was 60–80% and their properties *in vitro* were different from those in the A9 area and the striatum. However, recent direct reprogramming technology using neural factors on fibroblasts or iPS cells showed rapid production, nearly 100% purity, and functional maturation of neurons (induced neurons; iNs) (Vierbuchen *et al.* 2010; Caiazzo *et al.* 2011; Zhang *et al.* 2013). Therefore, inducing neural transcription factors on fibroblasts or iPS cells has a potential to achieve neuronal potential like adult neurons.

Furthermore, major challenges in modeling neurological disease focused on genetic disorders. However, most neurological disorders are mainly polygenic and dependent of environmental factors. To address those common diseases using iPS technology, it is because of make epigenetic modulation and/or common variant on iPS cell-derived neurons. Improving culture conditions to recapitulate the *in vivo* environment using tissue engineering techniques,

such as three dimensional culture system or microfluidics technology, is a need for future approaches.

## Conclusions

In this review, we turned our attention toward neurological disease-specific iPS cells and described the current status of research in the field. While there continue to be many issues that must be resolved from the standpoint of conducting iPS cell research, including generating homogenous populations of iPS cells and formulating methods of efficiently inducing and authenticating target cell types, research in this area has been expanding worldwide since the first report of the establishment of disease-specific iPS cells in 2008 (Dimos *et al.* 2008; Park *et al.* 2008; Bellin *et al.* 2012; Robinton and Daley 2012). Current research indicates that disease-specific iPS cell technology can accurately reflect conditions before the onset of clinical disease or, in many cases, during the initial stages of the disease. By combining disease-specific iPS cell technology with whole-genome analysis and non-invasive imaging technology, dramatic progress in the elucidation of pathogenetic mechanisms is expected. Moreover, applications in new drug development, as well as in sensitivity testing, safety testing, and toxicity testing of existing drugs, are likely to proceed at an accelerated pace through the use of disease-specific iPS cell technology. Our fervent hope is that the achievements in the field of disease-specific iPS cell research will be made available to all patients for whom no treatment of the underlying disease cause currently exists.

## Acknowledgements and conflict of interest disclosure

We thank all of the members of the Okano laboratory for their encouragement and support. This study was supported by the Program for Intractable Disease Research utilizing disease-specific iPS Cells from the Japan Science and Technology Agency (JST) to H.O. Dr H. Okano is a scientific consultant for San Bio, Inc., Eisai Co., Ltd, and Daiichi Sankyo Co., Ltd. Dr Y. Imaizumi is currently employed by Eisai Co., Ltd. The authors have no conflict of interest to declare.

## References

- An M. C., Zhang N., Scott G., Montoro D., Wittkop T., Mooney S., Melov S. and Ellerby L. M. (2012) Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. *Cell Stem Cell*, 253–263.
- Ananiev G., Williams E. C., Li H. and Chang Q. (2011) Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as *in vitro* disease model. *PLoS ONE* 6, e25255.
- Anrade L. N., Nathanson J. L., Yeo G. W., Menck C. F. and Muotri A. R. (2012) Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome. *Hum. Mol. Genet.* 21, 3825–3834.
- Bassik M. C., Kampmann M., Lebbink R. J. *et al.* (2013) A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. *Cell* 152, 909–922.
- Bellin M., Marchetto M. C., Gage F. H. and Mummery C. L. (2012) Induced pluripotent stem cells: the new patient?. *Nat. Rev. Mol. Cell Biol.* 13, 713–726.
- Benraiss A., Toner M. J., Xu Q. *et al.* (2013) Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease. *Cell Stem Cell* 12, 787–799.
- Bilican B., Serio A., Barmada S. J. *et al.* (2012) Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. *Proc. Natl Acad. Sci. USA* 109, 5803–5808.
- Brennan K. J., Simone A., Jou J. *et al.* (2011) Modelling schizophrenia using human induced pluripotent stem cells. *Nature* 473, 221–225.
- Caiazzo M., Dell'anno M. T., Dvoretzskova E. *et al.* (2011) Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature* 476, 224–227.
- Camnasio S., Delli Carri A., Lombardo A. *et al.* (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. *Neurobiol. Dis.* 46, 41–51.
- Chambers S. M., Fasano C. A., Papapetrou E. P., Tomishima M., Sadelain M. and Studer L. (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* 27, 275–280.
- Chang T., Zheng W., Tsark W., Bates S., Huang H., Lin R. J. and Yee J. K. (2011) Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. *Stem Cells* 29, 2090–2093.
- Cheung A. Y., Horvath L. M., Grafodatskaya D., Pasceri P., Weksberg R., Hotta A., Carrel L. and Ellis J. (2011) Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. *Hum. Mol. Genet.* 20, 2103–2115.
- Chiang C. H., Su Y., Wen Z., Yoritomo N., Ross C. A., Margolis R. L., Song H. and Ming G. L. (2011) Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. *Mol. Psychiatry* 16, 358–360.
- Cong L., Ran F. A., Cox D. *et al.* (2013) Multiplex genome engineering using CRISPR/Cas systems. *Science* 339, 819–823.
- Cooper O., Seo H., Andrabi S. *et al.* (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. *Sci. Transl. Med.* 4, 141ra190.
- Crompton L. A., Byrne M. L., Taylor H. *et al.* (2013) Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. *Stem Cell Res.* 11, 1206–1221.
- Devine M. J., Ryten M., Vodicka P. *et al.* (2011) Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. *Nat. Commun.* 2, 440.
- Dimos J. T., Rodolfa K. T., Niakan K. K. *et al.* (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science* 321, 1218–1221.
- Ebert A. D., Yu J., Rose F. F., Jr, Mattis V. B., Lorson C. L., Thomson J. A. and Svendsen C. N. (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. *Nature* 457, 277–280.
- Egawa N., Kitaoka S., Tsukita K. *et al.* (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. *Sci. Transl. Med.* 4, 145ra104.
- Farrer M., Chan P., Chen R. *et al.* (2001) Lewy bodies and parkinsonism in families with parkin mutations. *Ann. Neurol.* 50, 293–300.

- Fasano C. A., Chambers S. M., Lee G., Tomishima M. J. and Studer L. (2010) Efficient derivation of functional floor plate tissue from human embryonic stem cells. *Cell Stem Cell* **6**, 336–347.
- HD iPSC Consortium. (2012) Induced pluripotent stem cells from patients with Huntington's disease show cag-repeat-expansion-associated phenotypes. *Cell Stem Cell* **11**, 264–278.
- Higurashi N., Uchida T., Christoph L. *et al.* (2013) A human Dravet syndrome model from patient induced pluripotent stem cells. *Mol. Brain* **6**, 19.
- Imaizumi Y., Okada Y., Akamatsu W. *et al.* (2012) Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. *Mol. Brain* **5**, 35.
- Israel M. A., Yuan S. H., Bardy C. *et al.* (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* **482**, 216–220.
- Jang J., Kang H. C., Kim H. S. *et al.* (2011) Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. *Ann. Neurol.* **70**, 402–409.
- Jang M. H., Bonaguidi M. A., Kitabatake Y. *et al.* (2013) Secreted frizzled-related protein 3 regulates activity-dependent adult hippocampal neurogenesis. *Cell Stem Cell* **12**, 215–223.
- Jeon I., Lee N., Li J. Y. *et al.* (2012) Neuronal properties, *in vivo* effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. *Stem Cells* **30**, 2054–2062.
- Jiang H., Ren Y., Yuen E. Y. *et al.* (2012) Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. *Nat. Commun.* **3**, 668.
- Jiao J., Yang Y., Shi Y. *et al.* (2013) Modeling Dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons. *Hum. Mol. Genet.* **22**, 4241–4252.
- Juopperi T. A., Kim W. R., Chiang C. H., Yu H., Margolis R. L., Ross C. A., Ming G. L. and Song H. (2012) Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. *Mol. Brain* **5**, 17.
- Kano S., Colantuoni C., Han F. *et al.* (2013) Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. *Mol. Psychiatry* **18**, 740–742.
- Kawasaki H., Mizuseki K., Nishikawa S., Kaneko S., Kuwana Y., Nakanishi S., Nishikawa S. I. and Sasai Y. (2000) Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. *Neuron* **28**, 31–40.
- Koch P., Breuer P., Peitz M. *et al.* (2011) Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. *Nature* **480**, 543–546.
- Kondo T., Asai M., Tsukita K. *et al.* (2013) Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular abeta and differential drug responsiveness. *Cell Stem Cell* **12**, 487–496.
- Kriks S., Shim J. W., Piao J. *et al.* (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. *Nature* **480**, 547–551.
- Lee G., Papapetrou E. P., Kim H. *et al.* (2009) Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. *Nature* **461**, 402–406.
- Lee G., Ramirez C. N., Kim H. *et al.* (2012) Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. *Nat. Biotechnol.* **30**, 1244–1248.
- Li X. J., Du Z. W., Zarnowska E. D., Pankratz M., Hansen L. O., Pearce R. A. and Zhang S. C. (2005) Specification of motoneurons from human embryonic stem cells. *Nat. Biotechnol.* **23**, 215–221.
- Li L. B., Chang K. H., Wang P. R., Hirata R. K., Papayannopoulou T. and Russell D. W. (2012) Trisomy correction in down syndrome induced pluripotent stem cells. *Cell Stem Cell* **11**, 615–619.
- Liu G. H., Qu J., Suzuki K. *et al.* (2012a) Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. *Nature* **491**, 603–607.
- Liu J., Koscielska K. A., Cao Z. *et al.* (2012b) Signaling defects in iPSC-derived fragile X premutation neurons. *Hum. Mol. Genet.* **21**, 3795–3805.
- Liu Y., Liu H., Sauvey C., Yao L., Zarnowska E. D. and Zhang S. C. (2013a) Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells. *Nat. Protoc.* **8**, 1670–1679.
- Liu Y., Lopez-Santiago L. F., Yuan Y. *et al.* (2013b) Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. *Ann. Neurol.* **74**, 128–139.
- Mackay-Sim A. (2013) Patient-derived stem cells: pathways to drug discovery for brain diseases. *Front. Cell Neurosci.* **7**, 29.
- Mali P., Yang L., Esvelt K. M., Aach J., Guell M., DiCarlo J. E., Norville J. E. and Church G. M. (2013) RNA-guided human genome engineering via Cas9. *Science* **339**, 823–826.
- Marchetto M. C., Carroue C., Acab A., Yu D., Yeo G. W., Mu Y., Chen G., Gage F. H. and Muotri A. R. (2010) A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell* **143**, 527–539.
- Matsuda N., Sato S., Shiba K. *et al.* (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. *J. Cell Biol.* **189**, 211–221.
- Merkle F. T. and Eggan K. (2013) Modeling human disease with pluripotent stem cells: from genome association to function. *Cell Stem Cell* **12**, 656–668.
- Miller J. C., Tan S., Qiao G. *et al.* (2011) A TALE nuclease architecture for efficient genome editing. *Nat. Biotechnol.* **29**, 143–148.
- Mitne-Neto M., Machado-Costa M., Marchetto M. C. *et al.* (2011) Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. *Hum. Mol. Genet.* **20**, 3642–3652.
- Muotri A. R., Marchetto M. C., Coufal N. G., Oefner R., Yeo G., Nakashima K. and Gage F. H. (2010) L1 retrotransposition in neurons is modulated by MeCP2. *Nature* **468**, 443–446.
- Narendra D., Tanaka A., Suen D. F. and Youle R. J. (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J. Cell Biol.* **183**, 795–803.
- Nguyen H. N., Byers B., Cord B. *et al.* (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. *Cell Stem Cell* **8**, 267–280.
- Nihei Y., Ito D., Okada Y., Akamatsu W., Yagi T., Yoshizaki T., Okano H. and Suzuki N. (2013) Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophy. *J. Biol. Chem.* **288**, 8043–8052.
- Okada Y., Shimazaki T., Sobue G. and Okano H. (2004) Retinoic-acid-concentration-dependent acquisition of neural cell identity during *in vitro* differentiation of mouse embryonic stem cells. *Dev. Biol.* **275**, 124–142.
- Park I. H., Arora N., Huo H. *et al.* (2008) Disease-specific induced pluripotent stem cells. *Cell* **134**, 877–886.
- Patani R., Lewis P. A., Trabzuni D. *et al.* (2012) Investigating the utility of human embryonic stem cell-derived neurons to model ageing and neurodegenerative disease using whole-genome gene expression and splicing analysis. *J. Neurochem.* **122**, 738–751.

- Paulsen Bda S., de Moraes Maciel R., Galina A. *et al.* (2012) Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient. *Cell Transplant.* **21**, 1547–1559.
- Pedrosa E., Sandler V., Shah A., Carroll R., Chang C., Rockowitz S., Guo X., Zheng D. and Lachman H. M. (2011) Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. *J. Neurogenet.* **25**, 88–103.
- Rakovic A., Shurkewitsch K., Seibler P., Grunewald A., Zanon A., Hagenah J., Krainc D. and Klein C. (2012) PTEN-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem (iPS) cell-derived neurons. *J. Biol. Chem.* **288**, 2223–2237.
- Reinhardt P., Schmid B., Burbulla L. F. *et al.* (2013) Genetic correction of a LRRK2 mutation in human iPSCs links Parkinsonian neurodegeneration to ERK-dependent changes in gene expression. *Cell Stem Cell* **12**, 354–367.
- Ricciardi S., Ungaro F., Hambrock M. *et al.* (2012) CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. *Nat. Cell Biol.* **14**, 911–923.
- Robinton D. A. and Daley G. Q. (2012) The promise of induced pluripotent stem cells in research and therapy. *Nature* **481**, 295–305.
- Sanchez-Danes A., Richaud-Patin Y., Carballo-Carbajal I. *et al.* (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. *EMBO Mol. Med.* **4**, 380–395.
- Sawa A. and Cascella N. G. (2009) Peripheral olfactory system for clinical and basic psychiatry: a promising entry point to the mystery of brain mechanism and biomarker identification in schizophrenia. *Am. J. Psychiatry* **166**, 137–139.
- Seibler P., Graziotto J., Jeong H., Simunovic F., Klein C. and Krainc D. (2011) Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. *J. Neurosci.* **31**, 5970–5976.
- Shults C. W. (2006) Lewy bodies. *Proc. Natl Acad. Sci. USA* **103**, 1661–1668.
- Suzuki K., Mitsui K., Aizawa E. *et al.* (2008) Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors. *Proc. Natl Acad. Sci. USA* **105**, 13781–13786.
- Takahashi K. and Yamanaka S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**, 663–676.
- Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K. and Yamanaka S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**, 861–872.
- Urbach A., Bar-Nur O., Daley G. Q. and Benvenisty N. (2010) Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. *Cell Stem Cell* **6**, 407–411.
- Venkateshappa C., Harish G., Mythri R. B., Mahadevan A., Bharath M. M. and Shankar S. K. (2012) Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. *Neurochem. Res.* **37**, 358–369.
- Vierbuchen T., Ostermeier A., Pang Z. P., Kokubu Y., Sudhof T. C. and Wernig M. (2010) Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* **463**, 1035–1041.
- Weick J. P., Held D. L., Bonadurer G. F. 3rd *et al.* (2013) Deficits in human trisomy 21 iPSCs and neurons. *Proc. Natl Acad. Sci. USA* **110**, 9962–9967.
- Yagi T., Ito D., Okada Y., Akamatsu W., Nihei Y., Yoshizaki T., Yamanaka S., Okano H. and Suzuki N. (2011) Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum. Mol. Genet.* **20**, 4530–4539.
- Zhang N., An M. C., Montoro D. and Ellerby L. M. (2010) Characterization of human Huntington's disease cell model from induced pluripotent stem cells. *PLoS Curr.* **2**, RRN1193.
- Zhang J., Lian Q., Zhu G. *et al.* (2011) A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. *Cell Stem Cell* **8**, 31–45.
- Zhang Y., Pak C., Han Y. *et al.* (2013) Rapid single-step induction of functional neurons from human pluripotent stem cells. *Neuron* **78**, 785–798.
- Zhou H., Wu S., Joo J. Y. *et al.* (2009) Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* **4**, 381–384.



REVIEW

Open Access

# iPS cell technologies: significance and applications to CNS regeneration and disease

Hideyuki Okano<sup>1\*</sup> and Shinya Yamanaka<sup>2,3\*</sup>

## Abstract

In 2006, we demonstrated that mature somatic cells can be reprogrammed to a pluripotent state by gene transfer, generating induced pluripotent stem (iPS) cells. Since that time, there has been an enormous increase in interest regarding the application of iPS cell technologies to medical science, in particular for regenerative medicine and human disease modeling. In this review article, we outline the current status of applications of iPS technology to cell therapies (particularly for spinal cord injury), as well as neurological disease-specific iPS cell research (particularly for Parkinson's disease and Alzheimer's disease). Finally, future directions of iPS cell research are discussed including a) development of an accurate assay system for disease-associated phenotypes, b) demonstration of causative relationships between genotypes and phenotypes by genome editing, c) application to sporadic and common diseases, and d) application to preemptive medicine.

**Keywords:** Induced pluripotent stem cell, Cell transplantation, Spinal cord injury, Modeling human diseases, Parkinson's disease, Alzheimer's disease

## The development of induced pluripotent stem (iPS) cell technologies and their significance

The 2012 Nobel Prize in Physiology or Medicine was awarded for "The discovery that mature cells can be reprogrammed to become pluripotent." First, we would like to consider the significance of this research. The lives of mammals, including humans, begin with the fertilization of an egg by a sperm cell. In humans, a blastocyst composed of 70-100 cells forms by approximately 5.5 days after fertilization. The blastocyst is composed of the inner cell mass, the cell population that has the ability to differentiate into the various cells that constitute the body (pluripotency), and the trophoblast, the cells that develop into the placenta and extra-embryonic tissues and do not contribute cells to the body. In the embryonic stage, the pluripotent cells of the inner cell mass differentiate into the three germ layers, endoderm, mesoderm, and ectoderm, which will form specific organs and tissues containing somatic stem cells with limited differentiation potencies. These somatic stem cells continue to divide and

differentiate, and, by adulthood, an individual composed of 60 trillion cells is produced. Somatic stem cells born in the fetal period actively divide, and are involved in the formation and growth of various organs. However, even in the adult, somatic stem cells persist in niches in every organ and tissue, and play an important role in maintaining organ and tissue homeostasis. When cells in the inner cell mass are removed at the blastocyst stage and cultured *in vitro*, pluripotent embryonic stem (ES) cells are obtained. Thus, in the normal process of development, cell differentiation of the three germ layers proceeds from the simple stages of the fertilized egg and blastocyst, and ultimately produces an individual consisting of a complex cellular society.

In 1893, August Weismann argued that only germ cells (eggs and spermatozoa) maintain a "determinant," which was described as heritable information essential to decide on the functions and features of all somatic cells in the body [1]. In his germ plasm theory, the determinants are lost or irreversibly inactivated in differentiated somatic cells.

It took more than 50 years for researchers to rewrite this dogma. In 1962, Sir John Gurdon demonstrated the acquisition of pluripotency by reprogramming cells to their initial stage using a novel research technique, i.e.,

\* Correspondence: hidokano@a2.keio.jp; yamanaka@cira.kyoto-u.ac.jp

<sup>1</sup>Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

<sup>2</sup>Center for iPS Cell Research & Application, Kyoto University,

53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

Full list of author information is available at the end of the article




producing cloned individuals by transferring somatic cell nuclei into eggs [2]. However, for many years, that result was regarded as a special case limited to frogs alone. The production of Dolly the sheep by transferring the nucleus of a somatic cell (mammary gland epithelial cell) by Sir Ian Wilmut in the late 1990s [3] showed that cloning could also be applied to mammals.


These brilliant previous works led to our studies that culminated in the induction of pluripotency in mouse somatic cells in 2006, using retroviral vectors to introduce four genes that encode transcription factors i.e., *Oct4*, *Sox2*, *Klf4*, and *c-Myc*. We designated these cells as iPS cells [4]. In 2007, we succeeded in generating human iPS cells using genes encoding the same four transcription factors [1]. The results of this research showed that although the developmental process was thought to be irreversible, by introducing key genes into differentiated adult cells the cells could be reset to a state in the extremely early stage of development in which they possessed pluripotency. That is, the results demonstrated that the differentiation process was reversible. This startling discovery made it necessary to rewrite the embryology textbooks.

Three major lines of research led us to the production of iPS cells [5] (Figure 1). The first, as described above, was nuclear reprogramming initiated by Sir John Gurdon in his research of cloning frogs by nuclear transfer in 1962 [2] and by Sir Ian Wilmut, who cloned a mammal for the first time in 1997 [3]. In addition, Takashi Tada showed that mouse ES cells contain factors that induce reprogramming in 2001 [6]. The second line of research was factor-mediated cell fate conversion, initiated by Harold Weintraub, who showed that fibroblasts can be converted into the muscle lineage by transduction with the *MyoD*

gene, which encodes a muscle lineage-specific basic helix-loop-helix transcription factor in 1987 [7]. The third line of research was the development of mouse ES cells, initiated by Sir Martin Evans and Gail Martin in 1981 [8,9]. Austin Smith established culture conditions for mouse ES cells and identified many factors essential for pluripotency including leukemia inhibitory factor (LIF) in 1988 [10]. Later, he developed the method to induce the ground state of mouse ES cell self-renewal using inhibitors for mitogen-activated protein kinase and glycogen synthase kinase 3 [11], which supports the establishment of fully reprogrammed mouse iPS cells. Furthermore, James Thomson generated human ES cells [12] and established their optimal culture conditions using fibroblast growth factor-2 (FGF-2). Without these previous studies, we could never have generated iPS cells. Interest rapidly escalated, and, in tandem with the birth of iPS cell technology, pluripotency leapt into the mainstream of life sciences research in the form of “reprogramming technology” [13]. However, there remain many unanswered questions regarding reprogramming technology. What are the reprogramming factors in the egg cytoplasm that are active in cloning technology? What do they have in common with the factors required to establish iPS cells and what are the differences? What kind of epigenetic changes occur in association with the reprogramming?

Apart from basic research in embryology, broad interest has been drawn to the following possible applications of iPS cell research: (1) regenerative medicine, including elucidating disease pathologies and drug discovery research using iPS cell disease models, and (2) medical treatments (Figure 2). In this review, we describe these potential applications in the context of the results of our own research.





### Applications of iPS cell technologies to regenerative medicine

#### General statement of iPS-based cell therapy

iPS cells can be prepared from patients themselves and therefore great expectations have been placed on iPS cell technology because regenerative medicine can be implemented in the form of autografts presumably without any graft rejection reactions. Although there have been some controversies [14], the immunogenicity of terminally differentiated cells derived from iPS cells can be negligible [15-17]. Moreover, there has been substantial interest in the possibility of regenerative medicine without using the patient's own cells; that is, using iPS cell stocks that have been established from donor somatic cells that are homozygous at the three major human leukocyte antigen (HLA) gene loci and match the

patient's HLA type [18]. The development of regenerative medicine using iPS cells is being pursued in Japan and the USA for the treatment of patients with retinal diseases, including age-related macular degeneration [19], spinal cord injuries [17], Parkinson's disease (PD) [20,21], corneal diseases [22-24], myocardial infarction [25,26], diseases that cause thrombocytopenia, including aplastic anemia and leukemia [27,28], as well as diseases such as multiple sclerosis (MS) and recessive dystrophic epidermolysis bullosa [29] (Table 1).


#### Regenerative medicine research to discover a treatment for spinal cord injury (SCI) by means of iPS cell technologies

In 1998, Hideyuki Okano, in collaboration with Steven Goldman, demonstrated for the first time the presence of neural stem/progenitor cells (NS/PCs) in the adult human brain using a neural stem cell marker, the ribonucleic acid (RNA)-binding protein Musashi1 [30,31]. Research on nerve regeneration then commenced in earnest. That same year, we began regenerative medicine research on neural stem cell transplantation in a rat model of SCI, and have since made progress in developing NS/PC transplantation therapies in experiments on animal models of SCI. First, motor function was restored by transplanting rat fetal central nervous system (CNS)-derived NS/PCs into a rat SCI model [32]. The same study also showed that the sub-acute phase is the optimal time for NS/PC transplantation after SCI. In this study, at least part of the putative mechanism by which NS/PC transplantation restored function was identified in animal models of SCI. Both the cell autonomous

**Table 1** Planned clinical trials of iPS cell-based therapies

Principal investigator (Institute/Location)	Cell type to transplant	Target disorders
Masayo Takahashi, (RIKEN)	Retinal Pigment Epithelium (sheet)	Age-related macular degeneration (wet type)
Alfred Lane, Anthony Oro, Marius Wernig (Stanford University)	Keratinocytes	Recessive dystrophic epidermolysis bullosa (RDEB)
Mahendra Rao (NIH)	DA neurons	Parkinson's disease
Koji Eto (Kyoto University)	Megakaryocyte	Thrombocytopenia
Jun Takahashi (Kyoto University)	DA neurons	Parkinson's disease
Steve Goldman, (University of Rochester)	Oligodendrocyte precursor cell	Multiple Sclerosis
Hideyuki Okano, Masaya Nakamura (Keio University)	Neural stem/progenitor cells	Spinal Cord Injury
Shigeto Shimamura (Keio University)	Corneal endothelial cells	Corneal endothelial dysfunction
Koji Nishida (Osaka University)	Corneal epithelial cells (sheet)	Corneal epithelial dysfunction and trauma (e.g. Stevens-Johnson syndrome)
Yoshiki Sawa (Osaka University)	Cardiomyocytes (sheet)	Heart Failure
Keiichi Fukuda (Keio University)	Cardiomyocytes (sphere)	Heart Failure
Yoshiki Sasai and Masayo Takahashi (RIKEN)	Neuroretinal sheet including photoreceptor cells	Retinitis pigmentosa
Advanced Cell Technology	Megakaryocytes	Refractory thrombocytopenia

Representative studies of iPS-based cell therapy with planned clinical trials are listed. References: [17,19-29].



sole means of reproducing *ex vivo* phenomena that occur in patients *in vivo*, particularly for nervous system disorders. The result has been a tremendous desire by investigators who are conducting research on neurological diseases to become engaged in disease-specific iPS cell research [43-45].

A variety of disease-specific iPS cells have been used to study nervous system diseases, including amyotrophic lateral sclerosis (ALS) [46-48], spinal muscular atrophy [49], spinobulbar muscular atrophy [50], Friedreich's ataxia [51], Alzheimer's disease (AD) [52-54], PD [55-58], Huntington's disease [59,60], Machado-Joseph disease [61], fragile X-syndrome [62], Rett's syndrome [63], familial dysautonomia (FD) [64], Pelizaeus-Merzbacher disease [65], adrenoleukodystrophy [66], schizophrenia [67-69], and Dravet's syndrome of intractable epilepsy [70-72] (Table 2). In the following sections, we describe the results of nervous system disease-specific iPS cell research using PD and AD as examples [44].

#### Modeling PD with disease-specific iPS cells

PD is the second most common neurodegenerative disease after AD. More than 4 million patients are afflicted with PD globally. In Japan, its prevalence is about 100-150 cases per 0.5 million population [73]. PD is characterized by selective degeneration of dopaminergic (DA) neurons (A9 neurons) in the substantia nigra, which results in motor symptoms, including

tremor, rigidity, akinesia, and postural instability. The remarkable loss of neuromelanin-containing DA neurons in the substantia nigra pars compacta and the appearance of Lewy bodies (i.e., eosinophilic intracellular proteinaceous inclusions) are characteristic of PD and related diseases [74].

L-Dopa therapy or deep brain stimulation are current methods of treating PD, but they are not curative treatments. In most patients, the onset of PD occurs when the person is in their late 60s to early 70s; therefore, treatment of PD has become a major task in countries facing an aging society. Based on previous research, mutation of a specific gene is the cause of PD (familial PD [FPD]) in approximately 10% of PD patients, whereas the other 90% of patients have sporadic PD [73].

Interplay between genetic and environmental factors is likely to play an important role in the pathogenesis of PD. In human molecular genetic studies of rare monogenic forms of PD (FPD), at least 18 loci and 11 genes leading to the development of FPD have been identified. FPD-associated loci and genes for which there is conclusive evidence of a role in the disease mechanism include PARK1/PARK4 ( $\alpha$ -synuclein [SNCA]), PARK2 (Parkin), PARK6 (PTEN-induced kinase 1 [PINK-1]), PRAK7 (DJ-1), PARK8 (leucine-rich repeat kinase 2 [LRRK2]), and PARK9 (ATPase type 13A [ATP13A2]). The gene products are closely associated with the regulation of mitochondrial function and oxidative stress. Environmental risk factors

effect (such as synaptogenesis between graft-derived neurons and host-derived neurons) and non-cell autonomous (trophic) effects mediated cytokines released from the graft-derived cells are likely contributing to tissue repair and functional recovery. Subsequently, a non-human primate SCI model was developed using the common marmoset, and motor function in that model was restored by transplanting human fetal CNS-derived stem cells [33]. In the same study, a behavioral assay for motor function associated with SCI was developed. Based on these studies, a preclinical research system for cell transplantation therapy was established in a non-human primate SCI model.

Given these findings, we began preparations for clinical studies of human fetal CNS-derived NS/PC transplantation to treat SCI patients. However, with the guidelines for clinical research on human stem cells of the Japanese Ministry of Health, Labor and Welfare that came into effect in 2006, human fetus-derived cells and ES cells became ineligible for use in regenerative medicine. Thus, we had no choice but to change our strategy (human ES cells became eligible for use in the 2013 guidelines). In 2006, one of our research groups (Yamanaka's group) established iPS cells from adult mouse skin cells. Hypothesizing that it might be possible to induce NS/PCs from iPS cells, we (Okano's group) turned our attention to iPS cells as a means of obtaining NS/PCs without using fetal or ES cells. Based on conditions that were developed for experiments on mouse ES cells [34,35], NS/PCs were induced from mouse iPS cells [36]. The following year, we succeeded in restoring motor function by transplanting these mouse iPS cell-derived NS/PCs into a mouse model of SCI, and reported that when "good iPS cells" -derived NS/PCs, which had been pre-evaluated as non-tumorigenic by the transplantation into the brains of immunocompromised mice, were used for transplantation, motor function was restored for a long period of time without tumors developing [37]. In 2011, we succeeded in restoring motor function by transplanting human iPS cell-derived stem cells into a mouse SCI model [38]. Moreover, in 2012, motor function was restored by transplanting human iPS (line 201B7) cell-derived NS/PCs into the marmoset SCI model, and long-term motor function was recovered without observable tumor formation [39]. This finding was of great significance in terms of preclinical research, and provided a proof of concept that could potentially lead to a treatment method.

Collectively, when mouse or human iPS cells were induced to form NS/PCs and were transplanted into mouse or non-human primate SCI models, long-term restoration of motor function was induced, without tumorigenicity, by selecting a suitable iPS cell line [17,40]. Considering the sub-acute phase (2-4 weeks after the injury) as the optimal time for iPS cells-derived NS/PCs transplantation for SCI

patients, there are following major difficulties with autograft-based cell therapy. First, it takes about a few months to establish iPS cells. Second, it also takes three months to induce them into NS/PCs *in vitro*. Third, one more year would be required for the quality control including their tumorigenesis.

Considering these, our collaborative team (Okano and Yamanaka laboratories) are currently planning iPS-based cell therapy for SCI patients in the sub-acute phase using clinical-grade integration-free human iPS cell lines that will be generated by Kyoto University's Center for iPS Cell Research and Application (CiRA). We will establish a production method, as well as a storage and management system, for human iPS cell-derived NS/PCs for use in clinical research for spinal cord regeneration, build an iPS cell-derived NS/PC stock for regenerative medicine, establish safety screenings against post-transplantation neoplastic transformation, and commence clinical research (Phase I-IIa) trials for the treatment of sub-acute phase SCI (Figure 3). As these studies progress, the application of iPS cells to treat chronic phase SCI and stroke will be investigated. Significant therapeutic efficacy in the treatment of chronic phase SCI has not been achieved by cell transplantation alone [41]. However, clinical studies are planned using antagonists of axon growth inhibitors, such as Semaphorin3A inhibitors [42], followed by multidisciplinary rehabilitation combination therapies. We aim to perform a clinical trial based on the Pharmaceutical Affairs Act in collaboration with drug companies and to use iPS cell-derived NS/PC stocks for regenerative medicine to establish treatment methods for stroke, MS, and Huntington's disease.

## **iPS cell technologies in nervous system disease research**

### **General statement of human disease modeling with iPS cell technologies**

Lesion sites are difficult to access in patients with degenerative diseases of the nervous system. Therefore, in past studies, cell biological or biochemical analyses of their pathology centered on forced expression of the causative genes in non-nervous system cultured cell lines and on mice in which the causative gene was knocked out. However, in a few instances, the animal or cell models did not necessarily reflect the human pathology. Identifying cell biological or biochemical changes in the initial stages of the disease, before onset of symptoms, has been difficult given analyses conducted on postmortem brains. However, with the development of iPS cell technologies, it became possible to establish pluripotent stem cells from the somatic cells of anyone, irrespective of race, genetic background, or whether the person exhibits disease symptoms. Thus, it is no exaggeration to say that generation of disease-specific iPS cells using iPS cell technologies is the

**Table 2 Representative reports on neurological/psychiatric disorders**

Name of disease	Gene responsible	Cells responsible for pathogenesis	References
<b>Neurodevelopmental disorders</b>			
<i>Rett syndrome</i>	MeCP2, CDK5L5	Neurons, neural precursors	[63]
<i>Spinomuscular atrophy</i>	SMN1	Motor neurons	[49]
<i>Familial dysautonomia</i>	IKBKAP	Neural crest precursor cells	[64]
<i>Fragile X-syndrome</i>	FMR1	Neurons	[62]
<i>Adrenoleuko- dystrophy</i>	ABCD1	Oligodendrocytes	[66]
<i>Pelizaeus- Merzbacher disease</i>	PLP1	Oligodendrocytes	[65]
<i>Dravet syndrome</i>	SCN1A	Neurons	[70-72]
<b>Late-onset neurodegenerative disorders</b>			
<i>Alzheimer's disease</i>	PS1, PS2, APP, sporadic	Neurons	[52,53,58,100]
<i>Parkinson's disease</i>	$\alpha$ -synuclein, PARKIN, PINK-1, LRRK2 etc. sporadic	Dopaminergic neurons	[55-59,83,87]
<i>Amyotrophic lateral sclerosis</i>	SOD1, TDP43, FUS, C9ORF etc. sporadic	Motor neurons, astroglia	[47-49]
<i>Spinobulbar muscular atrophy</i>	Androgen receptor	Motor neurons, skeletal muscles	[50]
<i>Huntington's disease</i>	HTT	Glutamatergic neurons, GABAergic neurons	[59,60]
<i>Machado-Joseph disease</i>	ATX3	Glutamatergic neurons	[61]
<b>Psychiatric disorders</b>			
<i>Schizophrenia</i>	22q11.2, sporadic	Glutamatergic neurons, GABAergic neurons, dopaminergic neurons, etc.	[67-69]

Extracted and modified from References [43,44] and [73].

for PD include drinking well-water, and exposure to pesticides, herbicides, and heavy metals (Fe, Cu, and Zn). Furthermore, parkinsonism can be experimentally induced by administration of certain drugs, including MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), which is metabolized to MPP<sup>+</sup> in glial cells and blocks mitochondrial functions. The mechanisms common to the involvement of both genetic factors and environmental factors in causing PD are mitochondrial dysfunctions and increased oxidative stress [73]. Notably, there are close associations between mitochondrial homeostatic mechanisms and the gene products encoded by the genetic loci that are correlated with FPD. DA neurons are constitutively exposed to oxidative stress, which damages mitochondria and impairs membrane depolarization. The lowered membrane potential of mitochondria leads to stabilization of the protein kinase PINK1 (PARK6) [75]. The stabilized PINK-1 then phosphorylates the PARKIN protein (PARK2) (a member of the E3 ubiquitin ligase family) [76-78] and recruits it from the cytoplasm to the outer membrane of the mitochondria, where it ubiquitinates mitochondrial outer membrane proteins, including VDAC1 [79]. Mitochondrial outer membrane proteins thus tagged are recognized by isolation membranes, which then fuse with lysosomes and are ultimately degraded by lysosomal enzymes. In addition, ATP13A2 (PARK9) [80] is an H<sup>+</sup>-ATPase involved in lysosomal acidification, which is necessary for lysosome function. Mitochondria damaged by exposure to oxidative stress are degraded by mitophagy.

The mutations in FPD result in impaired mitochondrial homeostatic mechanisms. We have generated iPS cells from FPD patients [58] to clarify the interaction between impaired mitochondrial homeostatic mechanisms and the development of PD. Okano's group has established iPS cells from cutaneous fibroblasts obtained from patients with the PARK2 form of FPD (Patient A: female with an exon 2-4 deletion mutation; Patient B: male with an exon 6-7 deletion mutation) by performing retroviral gene transduction (*Oct4*, *Sox2*, *Klf4*, and *c-Myc*). After selecting seven clones with good neuronal differentiation (PA1, PA9, PA22, PB1, PB2, PB17, and PB20), NS/PCs and tyrosine hydroxylase (TH)-positive DA neurons were induced from PARK2 patient-derived iPS cells and, as a control, from human ES cells and healthy adult-derived iPS cells. In investigating PARK2, patient-derived fibroblasts, iPS cells, NS/PCs, neurons, and DA neurons were used to examine multiple aspects, including the transcriptome, metabolome, proteome, and mitochondrial homeostasis [58,73].

Increased oxidative stress is usually involved in the pathogenesis of PD; therefore, oxidative stress was measured in PARK2 iPS cell-derived neurons. These cells exhibited increased oxidative stress accompanied by activation of the Nrf2 pathway, which exerts a cytoprotective role under conditions of reactive oxygen species accumulation. A metabolome analysis of glycolytic pathways, the tricarboxylic acid cycle, and pentose phosphate pathways suggested that mitochondrial were dysfunctional in

the PARK2-derived neurons (H.O., unpublished results). Further characterization of mitochondria in the PARK2 iPS cell-derived neurons revealed abnormal mitochondrial morphology and impaired mitochondrial turnover.

Lewy bodies, a pathology characteristic of PD, and their main component,  $\alpha$ -synuclein, were investigated in PARK2 patient-derived iPS cells [58]. Based on an analysis of patient brain autopsies, Lewy bodies were found to accumulate in the neurons of patients with sporadic PD. However, while there have been several autopsy reports for brains of PARK2 patients,  $\alpha$ -synuclein was not generally thought to accumulate in the brain in PARK2 FPD. When the postmortem brain of a PARK2 patient was examined histologically, Lewy bodies and aggregates of  $\alpha$ -synuclein were confirmed, and examination of neuronal cells derived from iPS cells of the same patient revealed that  $\alpha$ -synuclein had accumulated in a similar manner [58]. These results were the first to demonstrate that patient iPS cell-derived neuronal cells faithfully reproduced a phenomenon that occurred in the brain of the same patient.

There is growing interest in genome editing of human iPS cells in introducing mutations into isogenic iPS cells (reviewed in [81]) and in rescue experiments via genetic repair, as methods to demonstrate genotype-phenotype causal relationships in human genetic disorders (discussed in iPS cell technologies in nervous system disease research and Conclusion) (Figure 2). Various PD-associated abnormalities, including neurite outgrowth abnormalities, DA neuron death induced by the addition of 6-hydroxydopamine, tau and  $\alpha$ -synuclein deposition, and gene expression changes in DA neurons, have been observed in DA neurons derived from iPS cells prepared from a patient with a LRRK2 gene mutation (G2019S mutation) and in isogenic control iPS cells in which the G2019S mutation was introduced. These PD-associated phenotypes were rescued by genetic correction of the LRRK2 mutation in the patient-derived iPS cells [82].

Studies of PD using iPS cell technology have shown the presence of PD-associated abnormalities in: 1) mitochondrial function, 2) the unfolded protein response and Golgi to endoplasmic reticulum transport and 3) axonal transport and cytoskeletal and neurite extension/retraction responses (Courtesy of Dr. Ole Isacson, Harvard Medical School). Thus, iPS-cell-based disease modeling is expected to contribute to the elucidation of the pathophysiology of PD, and be useful in drug screening and the development of methods for extremely early diagnosis, before the appearance of motor symptoms.

#### AD

AD accounts for approximately half of all cases of dementia and is the most common intractable neurological disease. AD is usually first manifested by a memory

disorder in a person aged 65 years or older. AD always progresses to disorientation and a decreased ability to comprehend and make judgments, and ultimately leads to personality disorders and a bedfast state. In recent years, early-onset AD, in which onset occurs from the fifth decade of life onward, has also attracted attention. People with early-onset AD lose the ability to conduct their daily lives and need long-term care; therefore, this disease has become a major social problem. Current treatment is primarily symptomatic, and the development of curative treatments has been slow. There are currently no prospects for a complete cure [44].

Based on previous research, it is clear that large amounts of amyloid beta ( $A\beta$ ) accumulate in the brains of AD patients and cause pathological changes called senile plaques. Moreover, experiments conducted on cell cultures and mice suggest that the highly toxic  $A\beta$ -42 may be overproduced in AD. The "amyloid hypothesis", which states that  $A\beta$  is the cause of the disease, has been difficult to verify in living nerve cells of patients using previous technologies. In collaboration with the Keio University neurology department team (Drs. Takuya Yagi and Daisuke Ito, Professor Norihiro Suzuki, and colleagues), we produced iPS cells from skin fibroblasts of familial AD (FAD) patients (presenilin (PS)-1 or -2 mutations) and succeeded in inducing neuronal cells for the first time [52]. We confirmed that these patient-derived neuronal cells produce twice the normal level of the highly toxic  $A\beta$ -42. This result correlated with  $A\beta$  accumulation in neural cells derived from living patients with AD. In addition, we treated AD iPS cell-derived neuronal cells with a  $\gamma$ -secretase modulator, which is a candidate drug for the treatment of AD, and showed that production of  $A\beta$ -42 was inhibited. Thus, these disease-specific iPS cells enabled a novel drug to be developed for the treatment of dementia [44].

In a study by Israel et al.,  $A\beta$  accumulation in neural cells induced from sporadic AD patient-derived iPS cells [53] was similar to our finding showing that in neural cells induced from FAD patient-derived iPS cells [52]. Accumulation of phosphorylated tau, in addition to  $A\beta$ , was observed in the neurons induced from iPS cells of one of the sporadic AD patients [53]. Gene analysis data were not described in this report [53], but the phosphorylated tau phenotype was not detected in FAD-derived neurons that had a PS1 or PS2 gene mutation [52]. These observations are extremely interesting from the standpoint of the diversity of AD phenotypes. Based on these results, AD pathology can be detected in sporadic AD, as well as FAD, and will lead to the development of new treatments [44].

In addition, Dr. Haruhisa Inoue's research group at CiRA produced iPS cells from the skin cells of patients with a mutation in the amyloid precursor protein (APP)

gene, which is a causative gene in early-onset (familial) AD, and from patients with late-onset (sporadic) AD who had no family history of AD. The mutant APP iPS cells were induced to differentiate into cerebral neurons. When a mutation called APP-E693Δ was present, the Aβ protein formed oligomers, accumulated in cells, induced endoplasmic reticulum and oxidative stress, and caused induction of the cell death gene Caspase4. Intracellular stress and neuronal cell death were inhibited by the unsaturated fatty acid docosahexaenoic acid (DHA), which is present at high levels in fish oils. Moreover, intracellular Aβ oligomers and cell stress have also been observed in some patients with late-onset sporadic AD, similar to the APP-E693Δ cells. Based on the analysis of neurons induced from iPS cells derived from several patients, there is an AD population in which DHA is effective and an AD population in which it is not. These findings suggest a diversity of pathologies in AD and, correspondingly, the need for a diversity of treatment strategies [44,54].

Monogenic FAD is rare in comparison to the sporadic form. However, genetic predisposing factors, for example ApoE, are present in sporadic AD. ApoE4 is the major known genetic risk factor for AD. ApoE is one of the five main types of blood lipoproteins (A-E) with 299 amino acids, with three different isoforms (ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158) and ApoE4 (Arg112, Arg158)) [83]. Genetic polymorphism of the *ApoE* gene is responsible for the generation of these isoforms [84]. While *ApoE4* allele is found in approximately 14% of the population [85], the *ApoE4* allele is genetically associated with late-onset familial and sporadic forms of AD [86], highlighting the importance of *ApoE4* in the pathogenesis of AD. In the future, the role of *ApoE4* should be characterized by a combination of iPS cell technologies and genome editing.

#### Future tasks for iPS cell researchers with regard to modeling human diseases

As described above, iPS cell researchers have developed new strategies to study the pathophysiology of human diseases and to provide assay systems for drug screening. However, many tasks remain to be accomplished to enable iPS cell technologies to accurately model human diseases and to develop new therapeutic interventions.

##### a) **Development of an accurate assay system for disease-associated phenotypes**

One of the problems with current iPS cell technologies is that the somatic cells generated from undifferentiated iPS cells remain immature for long periods. As a result, iPS cell technologies have been most successful in modeling pediatric or early-onset diseases, including FD [64], epilepsy (e.g., Dravet syndrome [70-72]), and Rett syndrome [63]. A

potential problem with current iPS cell technologies in modeling late-onset neurodegenerative diseases is the difficulty in obtaining age-related phenotypes in a relatively short timeframe. Lorenz Studer's group recently succeeded in inducing rapid cell aging by mis-expression of progerin, a truncated form of lamin A that is associated with premature aging [87]. This method made it possible to induce aging in PD patient iPS cell-derived DA neurons that resulted in disease-related phenotypes, including severe dendrite degeneration, progressive loss of TH-positive cells, and abnormal mitochondria or Lewy body precursor-like inclusions, which are difficult to identify using conventional neuronal differentiation methods for iPS cells [87]. Notably, we did not observe any Lewy bodies in DA neurons induced from PD patient-derived iPS cells [58], even though α-synuclein accumulated in progerin-expressing DA neurons *in vitro* [87] and Lewy bodies were prominent in the brain autopsy of the patient [58]. Although α-synuclein is their major component, Lewy bodies contain several other components including neurofilaments and ubiquitin [74,88,89]. These observations indicate that Lewy body formation is a dystrophic age-related event, and, thus, Lewy bodies may not form in DA neurons induced from PD patient-derived iPS cells by conventional culture methods. Thus, progerin-induced aging is a versatile method to investigate the features of late-onset age-related diseases by iPS cell-based disease modeling, while their application to other age-related diseases needs to be verified.

##### b) **Demonstration of causative relationships between genotypes and phenotypes by genome editing**

As a result of the rapid progress in human genome sequencing since the advent of next-generation sequencers, enormous numbers of disease-related mutations and single-nucleotide polymorphisms (SNPs) have been identified. Heterogeneity in the genetic mutations associated with some diseases is common. In most diseases, there is no formal proof of a causal relationship between the genetic mutation and the disease phenotype because experimental genetic studies are not possible in humans, as opposed to animal models, such as *Drosophila* and mouse. However, demonstration of a causal relationship between a genetic mutation and a disease phenotype can be verified using genome editing technologies such as the helper-dependent adenoviral vector [90], zinc-finger nucleases [91], transcription activator-like effector nucleases [92,93], or the CRISPR-Cas9 system [94,95] or its improved method [96]. These technologies can be used to perform rescue experiments with gene corrections,

as well as recapitulation of the disease phenotype by introducing disease-related mutations into control iPS cells [82]. Thus, while genome editing is a powerful technology for demonstrating genotype-phenotype causal relationships, the current genome editing techniques can only be applied to monogenic disorders, and new technologies will need to be developed to investigate polygenic disorders.

**c) Application to sporadic and common diseases**

Although Mendelian inheritance patterns have been well documented in several neurodegenerative diseases, including PD, AD, and ALS, the majority of the cases of these diseases are sporadic, and the genetic defects responsible for these cases remain to be identified [97]. In Mendelian diseases, the effect of genetic variation is extremely large, while the allele frequency is extremely low. Thus, Mendelian diseases are well suited for iPS cell-based disease modeling and genome editing. By contrast, the molecular etiology of most sporadic neurodegenerative diseases remains unknown. In a series of studies of the human genetics of sporadic diseases, genome-wide association studies (GWAS) with SNPs have been conducted as a means of identifying susceptibility genes for sporadic neurodegenerative diseases. Remarkably, these GWAS studies have succeeded in identifying disease-related rare variants with a high odds ratio [97]. For example, the glucocerebrosidase (GBA) gene polymorphism was identified as a robust genetic risk factor for PD [98]. It will be important to characterize the role of GBA mutations from the standpoint of the molecular etiology of PD, using iPS cell-based *in vitro* characterization. Since their effect size is not small, such sporadic diseases with rare genetic variants are also likely to be suitable targets for iPS cell-based disease modeling. However, it will be important to establish iPS cells from a sufficient number of patients and to characterize a large number of clones to perform statistical analyses. Therefore, it will be essential to develop large-scale automated systems for the production and differentiation of iPS cells.

**d) Application to preemptive medicine**

iPS cell-based disease modeling could play an important role in the early diagnosis of late-onset neurodegenerative diseases such as AD and PD. Since the motor symptoms of PD do not develop until almost 70% of the DA neurons in the substantia nigra have been lost, the molecular mechanisms that predominate during the initial stages of PD remain unknown. However, studies characterizing iPS cells derived from the somatic cells of PD patients have provided an excellent opportunity and excellent tools to investigate the course of changes

during PD, from the asymptomatic phases through to the later stages when the pathology has become prominent. Such studies could help to develop an appropriate preemptive neuroprotective treatment for PD, including small molecules, gene therapy, or cell therapy, which could be started early in the asymptomatic phase. AD usually has a long progression of more than 30 years that consists of an asymptomatic phase of ~20 years, a mild cognitive impairment (MCI) phase of ~10 years, and a dementia phase of unlimited length. Amyloid plaques form and continue to enlarge in the asymptomatic phase, and there is already substantial neuronal loss and brain atrophy in the MCI phase [99]. Thus, if diagnosis were possible in the asymptomatic phase, it would provide a great advantage by enabling the use of treatments to prevent dementia, including  $\gamma$ -secretase modulators [52], Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) [100], and DHA [54]. A combination of iPS cell-based phenotypic screening, whole genome sequencing by next-generation sequencing to identify AD-related polymorphisms, and imaging of A $\beta$  and tau by positron emission tomography would enable reliable diagnosis of AD in the asymptomatic phase. While obtaining a proof of concept for such preemptive treatments of AD would be difficult to obtain in a short time, we hope that such data can be obtained by using a combination of large-scale iPS cell-based disease modeling and a cohort study of dominantly inherited FAD, similar to the Dominantly Inherited Alzheimer Network (DIAN) study [101-103]. The development of preemptive treatments for late-onset neurodegenerative diseases would be enormously important in rapidly aging countries like Japan.

## Conclusions

As described above, since 2006, there have been enormous progresses in iPS cell technologies aiming for medical science, in both regenerative medicine and human disease modeling. Furthermore, iPS cell technologies could be applied for preemptive medicine. However, it is also true that iPS cell technologies have not yet saved any patients' lives at this moment in early 2014. Continuous efforts through the cooperation of basic stem cell biology, clinical investigation of diseases, translational research, pharmaceutical science, regulatory science and system biology will be necessary to let iPS cells really contribute to human health.

## Competing interests

H.O. is a paid scientific consultant to San Bio, Inc., Eisai Co., Ltd., and Daiichi Sankyo Co., Ltd. S.Y. is a member without salary of the scientific advisory boards of iPierian, iPS Academia Japan, Megakaryon Corporation and HEALIOS KK. Japan.

#### Authors' contributions

Both HO and SY wrote the manuscript and conducted the researches relevant to the present paper. All authors read and approved the final manuscript.

#### Acknowledgements

We thank all of the members of the Okano and Yamanaka laboratories for their encouragement and support. We are also grateful to Dr. Masaya Nakamura for providing a prototype graphic for Figure 3 and Prof. Ole Isacson at Harvard Medical School for valuable discussions. This study was supported by grants from the Program for Intractable Disease Research Utilizing Disease-specific iPSCs funded by the Japan Science and Technology Agency (JST) to H.O. and S.Y.

#### Author details

<sup>1</sup>Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. <sup>2</sup>Center for iPSC Cell Research & Application, Kyoto University, 53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. <sup>3</sup>Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.

Received: 14 February 2014 Accepted: 26 March 2014

Published: 31 March 2014

#### References

1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007, **131**(5):861–872.
2. Gurdon JB: The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. *J Embryol Exp Morphol* 1962, **10**:622–640.
3. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH: Viable offspring derived from fetal and adult mammalian cells. *Nature* 1997, **385**(6619):810–813.
4. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006, **126**(4):663–676.
5. Yamanaka S: Induced pluripotent stem cells: past, present, and future. *Cell Stem Cell* 2012, **10**(6):678–684.
6. Tada M, Takahama Y, Abe K, Nakatsuji N, Tada T: Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. *Curr Biol* 2001, **11**:1553–1558.
7. Davis RL, Weintraub H, Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 1987, **51**:987–1000.
8. Evans MJ, Kaufman MH: Establishment in culture of pluripotential cells from mouse embryos. *Nature* 1981, **292**:154–156.
9. Martin GR: Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A* 1981, **78**:7634–7638.
10. Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, Stahl M, Rogers D: Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. *Nature* 1988, **36**:688–690.
11. Ying QL, Wray J, Nichols J, Battle-Morera L, Doble B, Woodgett J, Cohen P, Smith A: The ground state of embryonic stem cell self-renewal. *Nature* 2008, **453**:519–523.
12. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM: Embryonic stem cell lines derived from human blastocysts. *Science* 1998, **282**:1145–1147.
13. Lensch MW, Mummery CL: From stealing fire to cellular reprogramming: a scientific history leading to the 2012 nobel prize. *Stem Cell Rep* 2013, **1**(1):5–17.
14. Zhao T, Zhang ZN, Rong Z, Xu Y: Immunogenicity of induced pluripotent stem cells. *Nature* 2011, **474**(7350):212–215.
15. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiyama M, Ideno H, Shimada A, Nifuji A, Abe M: Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. *Nature* 2013, **494**(7435):100–104.
16. Okita K, Nagata N, Yamanaka S: Immunogenicity of induced pluripotent stem cells. *Circ Res* 2011, **109**(7):720–721.
17. Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, Ikeda E, Yamanaka S, Miura K: Steps toward safe cell therapy using induced pluripotent stem cells. *Circ Res* 2013, **112**(3):523–533.
18. Turner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, Trounson A, Turner D, Yamanaka S, Wilmut I: Toward the development of a global induced pluripotent stem cell library. *Cell Stem Cell* 2013, **13**(4):382–384.
19. Kamao H, Mandai M, Okamoto S, Sakai N, Suga A, Sugita SJ, Kiryu JM, Takahashi M: Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. *Stem Cell Rep* 2014, **2**:1–14.
20. Kikuchi T, Morizane A, Doi D, Onoe H, Hayashi T, Kawasaki T, Saiki H, Miyamoto S, Takahashi J: Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. *J Parkinsons Dis* 2011, **1**(4):395–412.
21. Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y, Sekiguchi K, Nakagawa M, Parmar M, Takahashi J: Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. *Stem Cell Rep* 2014. in press.
22. Hayashi R, Ishikawa Y, Ito M, Kageyama T, Takashiba K, Fujioka T, Tsujikawa M, Miyoshi H, Yamato M, Nakamura Y, Nishida K: Generation of corneal epithelial cells from induced pluripotent stem cells derived from human dermal fibroblast and corneal limbal epithelium. *PLoS One* 2012, **7**(9):e45435.
23. Yoshida S, Yasuda M, Miyashita H, Ogawa Y, Yoshida T, Matsuzaki Y, Tsubota K, Okano H, Shimmura S: Generation of stratified squamous epithelial progenitor cells from mouse induced pluripotent stem cells. *PLoS One* 2011, **6**(12):e28856.
24. Hatou S, Yoshida S, Higa K, Miyashita H, Inagaki E, Okano H, Tsubota K, Shimmura S: Functional corneal endothelium derived from corneal stroma stem cells of neural crest origin by retinoic acid and Wnt/beta-catenin signaling. *Stem Cells Dev* 2013, **22**(5):828–839.
25. Egashira T, Yuasa S, Fukuda K: Induced pluripotent stem cells in cardiovascular medicine. *Stem Cells Int* 2011, **2011**:348960.
26. Kawamura M, Miyagawa S, Miki K, Saito A, Fukushima S, Higuchi T, Kawamura T, Kuratani T, Daimon T, Shimizu T, Okano T, Sawa Y: Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. *Circulation* 2012, **126**(11 Suppl 1):S29–S37.
27. Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K, Fujita KI, Koike T, Harimoto KI, Dohda T, Watanabe A, Okita K, Takahashi N, Sawaguchi A, Yamanaka S, Nakauchi H, Nishimura S, Eto K: Expandable megakaryocyte cell lines enable clinically-applicable generation of platelets from human induced pluripotent stem cells. *Cell Stem Cell* 2014, **14**(4):535–548.
28. Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M, Sawaguchi A, Nagai R, Takahashi K, Yamanaka S, Nakauchi H, Eto K: Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. *J Exp Med* 2010, **207**(13):2817–2830.
29. Garber K: Inducing translation. *Nat Biotechnol* 2013, **31**:483–486.
30. Sakakibara S, Imai T, Hamaguchi K, Okabe M, Aruga J, Nakajima K, Yasutomi D, Nagata T, Kurihara Y, Uesugi S, Miyata T, Ogawa M, Mikoshiba K, Okano H: Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. *Dev Biol* 1996, **176**(2):230–242.
31. Pincus DW, Keyoung HM, Harrison-Restelli C, Goodman RR, Fraser RA, Edgar M, Sakakibara S, Okano H, Nedergaard M, Goldman SA: Fibroblast growth factor-2/brain-derived neurotrophic factor-associated maturation of new neurons generated from adult human subependymal cells. *Ann Neurol* 1998, **43**(5):576–585.
32. Ogawa Y, Sawamoto K, Miyata T, Miyao S, Watanabe M, Nakamura M, Bregman BS, Koike M, Uchiyama Y, Toyama Y, Okano H: Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. *J Neurosci Res* 2002, **69**(6):925–933.
33. Iwanami A, Kaneko S, Nakamura M, Kanemura Y, Mori H, Kobayashi S, Yamasaki M, Momoshima S, Ishii H, Ando K, Tanioka Y, Tamaoki N, Nomura T, Toyama Y, Okano H: Transplantation of human neural stem cells for spinal cord injury in primates. *J Neurosci Res* 2005, **80**(2):182–190.
34. Naka H, Nakamura S, Shimazaki T, Okano H: Requirement for COUP-TFI and II in the temporal specification of neural stem cells in CNS development. *Nat Neurosci* 2008, **11**(9):1014–1023.
35. Okada Y, Matsumoto A, Shimazaki T, Enoki R, Koizumi A, Ishii S, Itoyama Y, Sobue G, Okano H: Spatiotemporal recapitulation of central nervous

- system development by murine embryonic stem cell-derived neural stem/progenitor cells. *Stem Cells* 2008, **26**(12):3086–3098.
36. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S: Variation in the safety of induced pluripotent stem cell lines. *Nat Biotechnol* 2009, **27**(8):743–745.
  37. Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S, Higashi H, Nagai T, Katoh H, Kohda K, Matsuzaki Y, Yuzaki M, Ikeda E, Toyama Y, Nakamura M, Yamanaka S, Okano H: Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. *Proc Natl Acad Sci U S A* 2010, **107**(28):12704–12709.
  38. Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, Kobayashi Y, Fujiyoshi K, Koike M, Uchiyama Y, Ikeda E, Toyama Y, Yamanaka S, Nakamura M, Okano H: Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. *Proc Natl Acad Sci U S A* 2011, **108**(40):16825–16830.
  39. Kobayashi Y, Okada Y, Itakura G, Iwai H, Nishimura S, Yasuda A, Nori S, Hikiyama K, Konomi T, Fujiyoshi K, Tsuji O, Toyama Y, Yamanaka S, Nakamura M, Okano H: Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. *PLoS One* 2012, **7**(12):e52787.
  40. Nakamura M, Okano H: Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. *Cell Res* 2013, **23**(1):70–80.
  41. Nishimura S, Yasuda A, Iwai H, Takano M, Kobayashi Y, Nori S, Tsuji O, Fujiyoshi K, Ebise H, Toyama Y, Okano H, Nakamura M: Time-dependent changes in the microenvironment of injured spinal cord affects the therapeutic potential of neural stem cell transplantation for spinal cord injury. *Mol Brain* 2013, **6**:3.
  42. Kaneko S, Iwanami A, Nakamura M, Kishino A, Kikuchi K, Shibata S, Okano HJ, Ikegami T, Moriya A, Konishi O, Nakayama C, Kumagai K, Kimura T, Sato Y, Goshima Y, Taniguchi M, Ito M, He Z, Toyama Y, Okano H: A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord. *Nat Med* 2006, **12**(12):1380–1389.
  43. Mattis VB, Svendsen CN: Induced pluripotent stem cells: a new revolution for clinical neurology? *Lancet Neurol* 2011, **10**(4):383–394.
  44. Okano H: Stem cells involved in disease researches and drug development. In *Brain Regeneration*. Edited by Okano H. Tokyo: Asakura Publishing Co., Ltd.; 2014:97–106. [Tsumoto T (Series Editor): Brain Science Library, Vol. 4] (In Japanese).
  45. Marchetto MC, Gage FH: Modeling brain disease in a dish: really? *Cell Stem Cell* 2012, **10**(6):642–645.
  46. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science* 2008, **321**(5893):1218–1221.
  47. Mitne-Neto M, Machado-Costa M, Marchetto MC, Bengtson MH, Joazeiro CA, Tsuda H, Bellen HJ, Silva HC, Oliveira AS, Lazar M, Muotri AR, Zatz M: Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. *Hum Mol Genet* 2011, **20**(18):3642–3652.
  48. Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, et al: Drug screening for ALS using patient-specific induced pluripotent stem cells. *Sci Transl Med* 2012, **4**(145):145ra104.
  49. Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN: Induced pluripotent stem cells from a spinal muscular atrophy patient. *Nature* 2009, **457**(7227):277–280.
  50. Nihei Y, Ito D, Okada Y, Akamatsu W, Yagi T, Yoshizaki T, Okano H, Suzuki N: Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophy. *J Biol Chem* 2013, **288**(12):8043–8052.
  51. Ku S, Soragni E, Campau E, Thomas EA, Altun G, Laurent LC, Loring JF, Napierala M, Gottesfeld JM: Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. *Cell Stem Cell* 2010, **7**(5):631–637.
  52. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N: Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum Mol Genet* 2011, **20**(23):4530–4539.
  53. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS: Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* 2012, **482**(7384):216–220.
  54. Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, et al: Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. *Cell Stem Cell* 2013, **12**(4):487–496.
  55. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schule B, Dolmetsch RE, Langston W, Palmer TD, Pera RR: LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. *Cell Stem Cell* 2011, **8**(3):267–280.
  56. Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D: Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. *J Neurosci* 2011, **31**(16):5970–5976.
  57. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW, Schapira AH, Gwinn K, Hardy J, Lewis PA, Kunath T: Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. *Nat Commun* 2011, **2**:440.
  58. Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, Nihira T, Kobayashi T, Ohyama M, Sato S, Takahashi M, Funayama M, Hirayama A, Soga T, Hishiki T, Suematsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shouji M, Nakanishi A, Suzuki N, Mizuno Y, Mizushima N, Amagai M, Uchiyama Y, Mochizuki H, Hattori N, Okano H: Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. *Mol Brain* 2012, **5**:35.
  59. Zhang N, An MC, Montoro D, Ellerby LM: Characterization of human huntington's disease cell model from induced pluripotent stem cells. *PLoS Curr* 2010, **2**:RRN1193.
  60. Egerioli A, Spits C, Simard JP, Hilven P, Haentjens P, Pearson CE, Sermon K: Huntington's and myotonic dystrophy hESCs: down-regulated trinucleotide repeat instability and mismatch repair machinery expression upon differentiation. *Hum Mol Genet* 2011, **20**(1):176–185.
  61. Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, Doerr J, Ladewig J, Mertens J, Tuting T, Hoffmann P, Klockgether T, Evert BO, Wullner U, Brustle O: Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. *Nature* 2011, **480**(7378):543–546.
  62. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N: Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. *Cell Stem Cell* 2010, **6**(5):407–411.
  63. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, Chen G, Gage FH, Muotri AR: A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell* 2010, **143**(4):527–539.
  64. Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, Tabar V, Sadelain M, Studer L: Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. *Nature* 2009, **461**(7262):402–406.
  65. Kuroiwa-Numasawa Y, Okada Y, Shibata S, Kishi N, Akamatsu W, Shoji M, Nakanishi A, Oyama M, Osaka H, Inoue K, Takahashi T, Yamanaka S, Kosaki K, Takahashi T, Okano H, Kuroiwa-Numasawa Y, Okada Y, Shibata S, Kishi N, Akamatsu W, Shoji M, Nakanishi A, Oyama M, Osaka H, Inoue K, Takahashi T, Yamanaka S, Kosaki K, Takahashi T, Okano H: Involvement of endoplasmic reticulum stress in dysmyelination of Pelizaeus-Merzbacher disease with PLP1 missense mutations shown by induced-pluripotent-stem cell-derived oligodendrocytes. *Stem Cell Rep* 2014. In Press.
  66. Jang J, Kang HC, Kim HS, Kim JY, Huh YJ, Kim DS, Yoo JE, Lee JA, Lim B, Lee J, Yoon TM, Park IH, Hwang DY, Daley GQ, Kim DW: Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. *Ann Neurol* 2011, **70**(3):402–409.